Syndax's axatilimab fails IPF trial's primary endpoint

October 12, 2026 4:01 PM

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found